Development asset linked to Shanghai Best-Link Bioscience in public FDA and regional records.
pharma · Small Cell Carcinoma of Lung
Shanghai Best-Link Bioscience
Shanghai Best-Link Bioscience drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Shanghai Best-Link Bioscience pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Best-Link Bioscience drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.